American Diabetes Association
Browse

IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity and associated with liver stiffness and fibrosis in fatty liver disease

Download (3.61 MB)
figure
posted on 2023-09-27, 22:06 authored by Aysim Gunes, Clémence Schmitt, Laurent Bilodeau, Catherine Huet, Assia Belblidia, Cindy Baldwin, Jeanne-Marie Giard, Laurent Biertho, Annie Lafortune, Christian Yves Couture, Angela Cheung, Bich N Nguyen, Eithan Galun, Chantal Bémeur, Marc Bilodeau, Mathieu Laplante, An Tang, May Faraj, Jennifer L. Estall

Many people living with diabetes also have non-alcoholic fatty liver disease (NAFLD). Interleukin-6 (IL-6) is involved in both diseases, interacting with both membrane-bound (classical) and circulating soluble receptors (trans-signaling). We investigated whether secretion of IL-6 trans-signaling co-receptors are altered in NAFLD by diabetes, and whether this might associate with the severity of fatty liver disease. Secretion patterns were investigated using human hepatocyte, stellate and monocyte cell lines. Associations with liver pathology were investigated in two patient cohorts: 1) biopsy-confirmed NASH and 2) class 3 obesity. We found that exposure of stellate cells to high glucose and palmitate increased IL-6 and sgp130 secretion. In line with this, plasma sgp130 in both patient cohorts positively correlated with HbA1c, and subjects with diabetes had higher circulating levels of IL-6 and trans-signaling co-receptors. Plasma sgp130 strongly correlated with liver stiffness and was significantly increased in subjects with F4 fibrosis stage. Monocyte activation was associated with reduced sIL-6R secretion. These data suggest that the hyperglycemia and hyperlipidemia can directly impact IL-6 trans-signaling, and that this may be linked to enhanced severity of NAFLD in patients with concomitant diabetes.

Funding

This work was supported by unrestricted operating grants from the Merck, Sharpe and Dohme Corporation/University of Montreal and the International Development Research Centre (108591-001). JLE and AT are supported by Chercheurs-boursiers: Senior awards from the Fonds de recherche du Québec Santé. The ULaval Biobank is supported by the IUCPQ Foundation and Research Center.

History